Health News
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4),
Read More
Medications
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. ROFERON-A 170927 Pre Filled Syringes contains the active ingredient interferon alfa-2a (rbe) Consumer Medicine Information
Read More